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Abstract
Background: Lung cancer is typically diagnosed at a late stage. Early presentation and detection of lung cancer
symptoms is critical to improving survival but can be clinically complicated and as yet a robust screening method
for diagnosis is not available in routine practice. Accordingly, the barriers to help-seeking behaviour and diagnosis
need to be considered. This review aimed to document the barriers to early presentation and diagnosis of lung
cancer, based on patient and carer perspectives.
Methods: A systematic review of databases was performed for original, English language articles discussing qualitative
research on patient perceived barriers to early presentation and diagnosis of lung cancer. Three major databases were
searched: Scopus, PubMed and EBSCOhost. References cited in the selected studies were searched for further relevant
articles.
Results: Fourteen studies met inclusion criteria for review. Barriers were grouped into three categories: healthcare
provider and system factors, patient factors and disease factors.
Conclusions: Studies showed that the most frequently reported barriers to early presentation and diagnosis
of lung cancer reported by patients and carers related to poor relationships between GPs and patients, a lack
of access to services and care for patients, and a lack of awareness of lung cancer symptoms and treatment.
Addressing these barriers offers opportunities by which rates of early diagnosis of lung cancer may be improved.
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Background
Lung cancer is one of the most common causes of death
from cancer worldwide [1]. It has been estimated that
nearly one in five deaths globally are due to lung cancer,
with 1.59 million deaths reported in 2012 (19.4% of the
total). Overall survival rates for lung cancer are poor,
with five year survival rates being 10–20% post diagnosis
in most countries including New Zealand, Canada,
Australia and Sweden [2–4]. A key reason for poor out-
comes in lung cancer survival is the fact that it is typic-
ally diagnosed at a late stage when the patient has
presented with symptoms. Population based screening
for early stage lung cancer using LDCT (low dose
computerised tomography) has been shown to be effect-
ive in identifying cases at an earlier stage and in redu-
cing lung cancer mortality [5]. However, there is a high
cost and a high false positive rate in using LDCT as a
screening test [6]. Consequently uptake has been very
slow and further research is ongoing in assessing
whether there are particular high risk populations where
screening for lung cancer can be justified.
An alternate strategy is to focus on the reason for late
diagnosis. These can be due to patient factors, system
factors and tumour factors [7]. Lung cancer symptoms
can be different from person to person, and while most
people show at least some early symptoms, some show
none [8, 9]. Moreover, symptoms particular to lung can-
cer may be subtle and not directly related to the lungs
and chest (e.g. tiredness and weight loss are sometimes
the presenting symptom) [8, 9]. Consequently, symptoms
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are often misinterpreted or misattributed by both patients
and General Practitioners (GPs). Misinterpretation can be
exacerbated by the existence of co-morbidities, which can
result in delayed diagnosis or referral [10–14]. Cross-cul-
tural variations across nine countries have shown differ-
ences in the delay in reporting symptoms, ranging from 7
days to 6 months [15]. Early recognition of lung cancer
symptoms combined with early medical help–seeking be-
haviour can have the potential to increase survival and de-
crease mortality from lung cancer [11, 16–18]. However,
the proportion of patients who are identified with early
stage cancer and receive curative surgery is low, with stud-
ies showing a prevalence of between 15 and 20% [19–22].
In saying this, recent research also points out that, al-
though shortening of diagnostic intervals can result in
clinical benefits for some patient groups (e.g. in terms of
diagnosis and post-diagnosis cancer management in pri-
mary care), for others, it may not necessarily translate to
improved outcomes. This can be due to various broader
reasons including the symptom signature of lung cancer
[9] or the patients’ perception of their experience within
the healthcare system [23].
Overall, to maximise patient survival from lung cancer,
early detection remains an imperative factor, alongside
prompt referral. It is therefore necessary to increase the
proportion of patients diagnosed with early stage disease.
However, numerous studies indicate that there are sig-
nificant barriers towards help-seeking behaviour and
diagnosis. The objective of this systematic review was to
explore and document the barriers to early presentation
and diagnosis of lung cancer, identified by patients and
carers (including those specific to indigenous and ethnic
minority groups).
Methods
Search strategy and selection criteria
Three major databases, Scopus (1960–2017), PubMed
(1945–2017) and EBSCOhost (1888–2017), were searched
from 23rd November to 8th December 2017, for papers
published in English prior to December, 2017. Text words
or keywords used in the search were “lung cancer” and
“barrier”, “obstacle”, “difficult* (difficulty)”, “problem”, or
“diagnos* (diagnosis/diagnostic)” combined with (i.e.,
AND) “general practi* (general practice/ practitioner)”,
“primary care”, or “family practice”. Inclusion criteria for
the extraction of articles from the databases were original,
qualitative studies, published in peer reviewed journals,
and a focus on patient and family or carer perceptions of
barriers to early presentation and diagnosis of lung cancer.
Accordingly, our exclusion criteria were literature reviews,
quantitative analyses, studies focusing solely on preven-
tion (e.g. screening) and a focus only on GP or health care
provider perceptions of barriers to lung cancer diagnosis.
It should be noted here, that our focus on only qualitative
analyses was to identify key themes relating to patient per-
ceived barriers to lung cancer diagnosis. By including
quantitative studies in our review, we would have risked
being in danger of leaving out important themes voiced by
patients themselves, as barriers identified based on quanti-
tative surveys or questionnaires tend to be predetermined.
Furthermore, our search did not extend to non-English
language studies or grey literature. References cited in the
selected studies and any literature reviews with broadly
similar search criteria were searched for further relevant
articles. Figure 1 shows a flow chart of the process of
selecting and including relevant studies for this review ac-
cording to the PRISMA guidelines [24].
The inclusion of articles published only in peer
reviewed journals was our first method of assessing the
quality each study reviewed. The quality of each study
was also assessed using the CASP checklist for qualita-
tive research [25]. All studies yielded generally strong
scores in the domains of validity, results and local rele-
vance or value.
Categorisation of perceived barriers
Walter et al’s [7] model for examining pathways to can-
cer diagnosis was used as a guide for identifying and
grouping barriers to diagnosis in the studies selected.
We particularly focused on the “contributing factors”
section of the model, which indicates that healthcare
provider and system factors, patient factors and disease
factors contribute to delays in cancer diagnosis and initi-
ation of treatment. It should be noted, however, that
while co-morbidities are listed under patient factors in
Walter et al’s [7] model, we included them as disease
factors in our review due to the nature of symptom
presentation particular to lung cancer, as discussed
previously.
Data extraction
The selected articles were reviewed and the following
data were extracted and compiled into a table: general
information about the article (authors’ names, year of
publication, and methodology); study location; partici-
pant information (participant group, ethnicity, and num-
ber of participants); and a brief description of the
findings, specifically the barriers to early presentation
and diagnosis of lung cancer relating to health care sys-
tem, patient and disease factors. A number of studies
that had multiple participant groups (i.e. patients, family
members, GPs and other service providers), explored
multiple types of cancer (i.e. lung, prostate, breast and
colorectal), used mixed methods (both qualitative and
quantitative), and had a primary focus that went beyond
identifying barriers to early presentation and diagnosis
(e.g. developing an intervention) were included, but
noted accordingly.
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Results
We identified 908 publications through our database
search, and an additional 20 from a manual reference list
search. By screening article titles, 870 were deemed to
be duplicates or irrelevant based on topic. The abstracts
of the remaining 58 articles were screened, from which
21 were excluded as they examined other cancers, not
including lung cancer. Full articles were assessed on the
remaining 37 potential publications. Of these, 23 were
excluded as they focused on lung cancer screening, they
did not examine patient and carer perspectives of bar-
riers to diagnosis and/or they were literature reviews or
quantitative analyses. The remaining 14 articles were in-
cluded in our review. The characteristics and results of
the studies are summarised in Table 1.
Six studies were undertaken in the United Kingdom
[10–12, 26–28], six in Australia [29–34], one in the
United States [35], and one in New Zealand [36]. The
ethnicities of the populations studied were European
(New Zealand European, “White British”, “White”),
Māori, Aboriginal and Torres Strait Island peoples,
“Black/Black British”, “Asian/British Asian”, Chinese,
“mixed” and other. Seven studies reported that they
recruited participants from hospitals, four from com-
munity or other support groups, three from General
Practices and one from a cancer register.
Five studies included multiple participant groups in-
cluding patients, family and/or community members,
GPs and other service providers [26, 29, 31, 32, 34].
However, as the purpose of this review was to identify
barriers to early presentation and diagnosis of lung can-
cer specifically by patients and families or carers, only
the statements made by these participants were included
in our analysis. Two studies focused on multiple types of
cancer including lung cancer [27, 30] – only statements
by participants with a lung cancer diagnosis were in-
cluded in this analysis. One study had a primary focus
on the development of an intervention to reduce time to
presentation with symptoms of lung cancer alongside
barriers to early presentation and diagnosis [26] - the
present review considered only the barriers, rather than
the intervention discussed in this article. One study in-
cluded patients with symptoms suggestive of lung can-
cer, including patients who had not yet received a lung
cancer diagnosis and patients post lung cancer diagnosis
[10] – this review considered only the barriers specific
Fig. 1 Process of literature selection for barriers to lung cancer diagnosis flow chart
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to patients post lung cancer diagnosis. Two studies used
mixed methods (both qualitative and quantitative) for
data collection [28, 30] – only qualitative data from
these studies were considered for the present review.
Healthcare provider and system factors as barriers to
early presentation and diagnosis were identified in 13 ar-
ticles, patient factors in 12 and disease factors in five.
The age and gender of participants were reported by
most articles. When reported, age was provided either as
an age range or mean age. Accordingly, participant age
ranged from 39 to 86 years, with mean age ranging from
60 to 79 years. A good gender mix was also included in
the studies reviewed.
Our findings were grouped into three categories:
healthcare provider and system factors, patient factors
and disease factors that serve as barriers to early presen-
tation and diagnosis of lung cancer. These categories
were based on the “contributing factors” section of
Walter et al’s [7] model, as discussed previously. The fol-
lowing sub-sections present our results for each category.
Healthcare provider and system factors
Healthcare provider and system factors included issues
relating to delivery and healthcare policy, and barriers to
access. Primarily, the quality of the relationship between
GPs and patients was a recurring theme reported in
many of the articles. For instance, a lack of an estab-
lished relationship between patient and GP affected the
quality of care provided to the patient. The quality of
communication between the patient and GP resulted in
a lack of established trust between patient and GP, a
lengthy period of time before GPs took the patient’s con-
cerns seriously and inadequate information provided to
patients [29, 33–36]. Such barriers were also exacerbated
by a lack of GP continuity [35, 36]. Specific barriers
identified were, GPs’ ‘nihilism’ towards lung cancer [36],
and inability to understand or relate to tobacco addic-
tion [33]. A New Zealand study also reported that a
lack of openness to other (indigenous/ ethnic minor-
ity) worldviews was a barrier to diagnosis of lung
cancer [36].
Broader system factors were also identified as barriers
(regardless of country level contexts), including difficulty
making or accessing appointments, discontinuity of care
(relating to GPs, specialists and/or other healthcare pro-
viders), long waiting times, patients getting delayed in
the system or difficulty faced by GP to get referrals for
specialists [26, 28, 34–36]. Patients additionally observed
that limited access to health care (provider and services)
was a barrier to diagnosis and care [10, 30, 34, 36].
Patients and carers also stated that GPs had inad-
equate knowledge of lung cancer symptoms and treat-
ment options available. A number of studies indicated
that GPs lacked knowledge about interpreting symptoms
and accessing appropriate treatment pathways [12, 36].
According to Black et al. [27], patients indicated that
their health care professional’s appraisal led to an in-
accurate re-evaluation of self-diagnosed symptoms (e.g.
symptoms of lung cancer being diagnosed as asthma).
Finally, Scott et al. [31] observed that in Australia, an
increased societal awareness of lung cancer as being
smoking related and being the ‘fault of the individual’, in-
creased stigma related to the condition and smoking,
thus serving as a barrier to seeking help. Moreover, ac-
cording to Tod et al. [11] in the United Kingdom, media
messages reinforced the fact that people should not use
primary care services unless a problem was extreme.
Patient factors
Patient factors included demographic, psychological, social
and cultural factors and previous experience. A key patient
related barrier recurrent in the literature was normalisation,
misattribution, misinterpretation, minimization or low risk
perception of symptoms relating to lung cancer [10–12, 29,
30, 33, 35, 36]. For instance, while many patients felt that
respiratory symptoms and generalized ill-health were nor-
mal for smokers, others felt that protective behaviours such
as exercise or diet could offset health risk. Consequently,
patients engaged in self-management of symptoms rather
than seeking medical advice [10, 35, 36].
Fatalistic beliefs and fear of death and/or cancer diag-
nosis were additionally reported as preventing patients
from seeking help, often due to patients’ lack of aware-
ness of lung cancer treatments [11, 31, 33, 35, 36]. Pa-
tients also indicated that perceived blame, stigma, guilt
and shame related to smoking and diagnosis functioned
as barriers [11, 28, 31, 33, 36]. Patients were put off visit-
ing healthcare professionals by perceptions that they
would be lectured or reprimanded to cease smoking
[33]. ‘Stoicism’ was also reported as a barrier, particularly
amongst men, where patients did not wish to complain,
instead, putting on a ‘brave face’ [11, 30].
Finally, barriers related to the financial aspects of can-
cer care, and thus patients’ socioeconomic status, such
as the high cost of health insurance or treatment and
care (e.g. in the United States and Australia), lack of
transport to healthcare centre (e.g. in rural Australia)
and competing responsibilities (e.g. in the United King-
dom) were identified as barriers to symptom presenta-
tion and diagnosis [10, 29, 32, 34, 35].
Disease factors
Disease factors included site, size and tumour growth
rate as well as symptom presentation. Five articles re-
ported disease factors. All of these studies indicated that
symptom presentation, specifically, the wide variation in
lung cancer symptoms and therefore a lack of a clear
symptom profile or a lack of symptom presentation
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overall, made both GP diagnosis and patient awareness
difficult [11, 12, 30, 36]. For example, Birth et al. (in
2014) [10] reported that the existence of co-morbidities
masked many of the symptoms indicative of lung cancer
(e.g. pain symptomatic of lung cancer was attributed to a
kidney infection based on patient’s history of gallstone
related pain, cough attributed to patient’s existing
chronic respiratory symptoms or allergy).
Discussion
This systematic literature review provided evidence that
the reasons for delays in early presentation and diagnosis
of lung cancer are complex and multifaceted. It is also
clear that all these factors (i.e. healthcare provider and
system, patient and disease) overlap. For instance, a key
patient and carer perceived barrier relates to the rela-
tionship between patients and GPs. Such relationships
are crucial to presentation and diagnosis of lung cancer,
as they affect the level of trust between GPs and pa-
tients, patient attitudes towards their GP and vice versa,
and patient perceived blame, stigma, lecturing and repri-
manding by GPs [29, 33, 35, 36]. Thus, barriers relating
to the relationship between patients and GPs span both
healthcare provider and system factors as well as patient
factors. Additionally, this review provided evidence that
issues relating to access, spanning both healthcare pro-
vider and system factors and patient factors, was another
key area that posed barriers to patients’ help-seeking be-
haviour [10, 26, 28, 32, 34, 36]. A lack of awareness of
lung cancer symptoms and treatment was also identified
as a significant barrier. Issues relating to a lack of awareness
spanned healthcare provider and system factors, patient
factors as well as disease factors, and affected patients, GPs
and the general public [11, 12, 27, 31, 32, 36].
There is a clear indication in the research of the press-
ing need to increase lung cancer awareness, and to pro-
vide resources and knowledge regarding symptoms and
treatment to patients, healthcare providers and the gen-
eral public. In particular, research by Tod et al. (2008)
[11], included in this review, indicates that some infor-
mation campaigns relating to lung cancer were seen to
contribute to fatalistic views due to a focus on death ra-
ther than treatment and/or survival. Since then, how-
ever, various awareness campaigns about the early
diagnosis and/or detection of lung cancer have been
trialled in New Zealand, Australia [37], Scotland [26]
and Doncaster, United Kingdom [38], some of which
have resulted in an increase in at-risk patients’ intentions
to see a GP and request a chest X-ray (e.g. [38]). The
programme implemented in Doncaster, additionally in-
volved a brief GP education intervention for primary
care practices in high lung cancer risk localities, result-
ing in an increase in chest X-rays and lung cancer diag-
nosis [38]. In many countries, clinical guidelines and
optimal care pathways specific to lung cancer exist,
aimed at increasing GP awareness of the disease (e.g. ac-
cording to the Ministry of Health, New Zealand [39]).
While such initiatives are promising, there is a need for
replication, rigorous outcome evaluation [40], and to
create a multi-pronged approach to raise lung cancer
awareness [36]. The findings of this review, as well as
that of quantitative, population level studies identifying
patient perceived barriers to lung cancer diagnosis, both
indicate that an inability to recognize symptoms and the
stigma associated with lung cancer posed significant bar-
riers to early diagnosis [41–44]. Thus, there is also a
need to provide education to patients about the risks
and symptoms of lung cancer, to dispel negative (fatalis-
tic and stigmatising) beliefs about the disease and out-
comes, and to empower at-risk patients to get checked
in primary care [36]. Such an approach needs to also in-
volve a GP training or education element, as an increase
in lung cancer awareness needs to occur in patients, the
general public as well as GPs and other healthcare
professionals.
Delays within the system were also identified as a
major barrier to presentation and diagnosis of lung can-
cer. For instance, delays in getting appointments, in
waiting times, in getting referrals, or getting a diagnosis,
the distance and access to health care providers, as well
as the financial aspects of cancer care (e.g. cost of treat-
ment, patients’ socioeconomic status) hindered access to
services, and thus timely diagnosis and treatment
[10, 28–30, 34–36]. Similar findings were reported
by Sood et al’s (2009) [45] review of patients’ clinical
records identifying barriers to diagnosis of lung can-
cer. Delay, irrespective of reason, can be frustrating
for many patients, and when combined with difficulties
accessing information and services, could increase distress
[46]. It is clear that a more patient-centred and accessible
approach to cancer diagnosis and care is needed.
Furthermore, many studies in our review did not re-
port the ethnicity, or rather the ethnic variation, of their
participants [10–12, 26, 29–31, 33–35]. In particular,
Sharf et al. (in 2005) [35] and Tod et al. (in 2008) [11]
indicated that the fact that their participant bases com-
prised primarily ‘white’ patients, rather than ‘black’ or
minority groups, was a limitation of their research. Con-
sidering the poorer outcomes relating particularly to eth-
nic minority and indigenous populations diagnosed with
lung cancer [47–52], the findings of this review imply
that more qualitative research needs to be conducted
and published with a specific focus on ethnic minority
and indigenous groups. These findings also hold implica-
tions for broader arguments emphasizing the importance
of culture, and of acknowledging and respecting diverse
worldviews, particularly in cancer care. For example, re-
search from Australia (not included in this review),
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indicates that a lack of cultural competence by GPs was
a significant barrier to early presentation and diagnosis
of cancer [53–56]. Such conclusions are consistent with
the statements of Māori participants in Walton et al’s
[36] New Zealand study, which indicated that a GP’s lack
of respect for, and openness to other (indigenous/ethnic
minority) worldviews posed a significant barrier to
help-seeking behaviour.
Accordingly, the New Zealand Medical Council has
made cultural competency training a specific core ex-
pectancy in ongoing medical education for doctors and
specialty training programmes, partly to address such is-
sues with indigenous communities [57]. In saying this, it
is important to recognise that a healthcare professional’s
cultural understanding of, and engagement with a pa-
tient should not be reduced to a simple set of technical
skills acquired solely through cultural competency train-
ing [58]. Accordingly, the findings of this review reiterate
the importance of the need for a focus on building rela-
tionships between patient and GP. As such, the Austra-
lian studies report that many Aboriginal Australians
hold differing health beliefs of cancer causation [53–56].
For instance, this can include a belief that cancer is con-
tagious, or simply the lack of a word for ‘cancer’, result-
ing in the diagnosis and its implications not being
understood by many of these groups [55]. Accordingly,
these researchers indicate that there needs to be an ac-
knowledgement of such differing worldviews by the
broader healthcare system, and that GPs need to also be
aware of the significance of traditional healing methods
germane to each of these communities [54, 56]. While
we acknowledge that not all indigenous communities are
the same, there is need for health professionals to have
knowledge of, and/or experience in, not only medicine,
but also the communities they serve, which goes beyond
a simple set of skills acquired through cultural compe-
tency training. Overall, more attention needs to be paid
to identifying and addressing barriers to early presenta-
tion and diagnosis of lung cancer among indigenous
communities.
A number of studies in this review also indicated that
patients, or potential participants of their research, died
prior to the commencement of interviews as a result of
lung cancer (e.g. [12, 29, 30]). This was listed as a limita-
tion of such studies. The fact that lung cancer patients
passed away within the short timeframe of a recruitment
process reinforces the importance and urgency of identi-
fying and addressing the barriers to early presentation
and diagnosis of lung cancer.
The strengths of this review were that it assessed 14
high quality studies from respected journals, bringing to-
gether statements from a total of 240 patients from five
countries and diverse populations. A limitation of this
review was that it only examined studies published in
English. However, the consistency of results identified in
these studies provides some reassurance as to their val-
idity. Studies reviewed were also from a limited number
of countries. Research from countries that are not con-
sidered First World nations may have contributed sig-
nificantly to our findings. Moreover, we documented
only the perceived barriers identified by patients and
carers. Patients and carers are the most valid source for
identifying barriers to early presentation and diagnosis
of lung cancer. However, understanding GP views along-
side population level data may be necessary in order to
introduce effective interventions.
Conclusion
Early presentation and detection of symptoms relating
to lung cancer is critical to improving survival. Delays in
early presentation and diagnosis of lung cancer might be
avoided if various barriers relating to healthcare provider
and system factors as well as patient and disease factors
are addressed. This paper provides a complete, exhaust-
ive summary of current patient-centred evidence identi-
fying the existent barriers to early diagnosis of lung
cancer, by bringing together and reviewing 14 qualitative
studies from various countries. According to the findings
of our review, a good starting point to addressing patient
and carer perceived barriers, is to focus on the three key
areas of relationship building between GP and patient,
improving patient access to services and care, and in-
creasing awareness of lung cancer symptoms and treat-
ment, particularly among disadvantaged communities.
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